advanced cholesterol panel inflammatory marker

Lipoprotein(a), often written as Lp(a), is a type of lipoprotein particle containing cholesterol and a protein called apolipoprotein(a). Elevated Lp(a) levels are an independent risk factor for heart attack and stroke, even in people with normal cholesterol. Lp(a) levels are largely genetic and cannot be significantly lowered by diet or exercise alone. This test identifies individuals at heightened cardiovascular risk who may benefit from additional preventive measures or specific medications to reduce their disease risk.

Pre-beta lipoprotein is an early-stage, cholesterol-carrying particle involved in lipid metabolism. Elevated pre-beta lipoprotein levels are associated with metabolic dysfunction, insulin resistance, and increased cardiovascular risk. This test is often ordered as part of advanced lipid profiling to assess your risk for heart disease beyond standard cholesterol measurements. High levels suggest your body may not be effectively processing fats and may benefit from lifestyle modifications or treatment.

Lipoprotein(a), or Lp(a), is a cholesterol-carrying particle with a genetic component that significantly influences cardiovascular risk. This test measures Lp(a) as a percentage of total lipoprotein, providing insight into your atherogenic lipid profile. High Lp(a) levels are an independent risk factor for heart attack and stroke, even in people with otherwise normal cholesterol. Unlike other lipids, Lp(a) is largely determined by genetics and is less responsive to diet and exercise, making it important for personalized heart disease risk assessment.

HDL-2 is a specific subtype of 'good' cholesterol that is particularly protective against heart disease. This specialized test uses ultracentrifugation to isolate and measure HDL-2 cholesterol specifically. Higher HDL-2 levels are associated with better cardiovascular health and lower risk of heart attack and stroke. While standard cholesterol panels measure total HDL, this advanced test provides more detailed information about HDL quality, helping clinicians assess detailed cardiovascular risk in patients with metabolic concerns or significant family histories of heart disease.

C-reactive protein (CRP) is an acute-phase protein produced by the liver in response to inflammation. Measured in serum or plasma, CRP is one of the most widely used markers of systemic inflammation. It rises rapidly (within hours) in response to bacterial infections, autoimmune flares, tissue injury, and malignancy. High-sensitivity CRP (hs-CRP) at lower levels is used for cardiovascular risk stratification. CRP is valuable for monitoring treatment response in rheumatologic conditions, infections, and post-surgical recovery. Unlike ESR, CRP responds quickly to changes in inflammatory status.

Oxidized LDL (oxLDL) is formed when LDL cholesterol particles undergo oxidative damage in the bloodstream. This modified form is more atherogenic—meaning it more readily accumulates in artery walls and triggers inflammation. Elevated oxidized LDL is considered a stronger predictor of cardiovascular disease risk than standard LDL cholesterol alone. This test is increasingly used in advanced cardiovascular risk assessment to identify individuals at higher risk for heart attack and stroke despite normal LDL levels.

percentile (of population)

Medium-sized beta lipoprotein subparticles are components of LDL (low-density lipoprotein) cholesterol. Advanced lipid tests measure the size and number of these particles, providing more detailed information than standard cholesterol tests. Increased levels of small, dense LDL particles are associated with greater cardiovascular risk, as these particles more easily penetrate artery walls. This test helps identify individuals at higher heart disease risk despite normal total cholesterol levels.

This test measures small, dense LDL cholesterol particles, a subset of low-density lipoprotein. Small, dense LDL particles are more atherogenic (damage-prone) than larger LDL particles and penetrate artery walls more easily, increasing cardiovascular risk. Elevated small dense LDL is associated with metabolic syndrome, insulin resistance, low HDL, and elevated triglycerides. This test provides more detailed cardiovascular risk assessment than standard LDL measurement alone, particularly useful for individuals with metabolic risk factors or family history of heart disease.

Remnant lipoproteins are cholesterol-rich particles that remain after triglycerides are removed from dietary particles in the bloodstream. Elevated remnant lipoprotein levels indicate impaired cholesterol metabolism and are associated with increased cardiovascular risk, independent of traditional cholesterol levels. High remnant lipoproteins suggest metabolic dysfunction, poor diet quality, or genetic predisposition. This test provides insight into heart disease risk beyond standard lipid panels and may warrant lifestyle changes or medication.

Lipoprotein midband B is an uncommon lipoprotein particle detected through specialized lipid testing. Its presence or elevation can indicate certain metabolic disorders or dyslipidemia patterns not visible on standard cholesterol panels. This test is typically ordered when routine lipid results are abnormal or when a patient has unusual cardiovascular risk factors despite normal standard cholesterol levels. Results help refine cardiovascular risk assessment and guide specialized lipid-lowering therapy if needed.

This test measures cholesterol specifically within HDL-3, a subclass of high-density lipoprotein (HDL). HDL is often called 'good cholesterol' because it helps remove excess cholesterol from your arteries. HDL-3 is smaller and denser than HDL-2, and higher HDL-3 cholesterol levels are associated with better cardiovascular protection. This detailed lipoprotein analysis helps assess your cardiovascular risk more precisely than standard cholesterol testing.

Pre-beta lipoprotein particles are small, dense lipoprotein particles involved in cholesterol transport. Large pre-beta subparticles are an emerging cardiovascular risk marker. These particles are often elevated in people with insulin resistance, elevated triglycerides, or metabolic syndrome. High levels are associated with increased atherosclerosis risk, even in individuals with normal total cholesterol. This advanced lipid test provides more detailed cardiovascular risk assessment than standard cholesterol panels.

Lipoprotein(a), or Lp(a), is a cholesterol-carrying particle in your blood that combines LDL cholesterol with a protein called apolipoprotein(a). Large Lp(a) particles may be less atherogenic (artery-damaging) than small particles. This test measures the concentration of large Lp(a) subparticles, which provides more detailed information about your cardiovascular risk. Elevated Lp(a) levels are genetically determined and are associated with increased risk of heart attack and stroke, independent of traditional cholesterol levels.

LDL cholesterol particles vary in size, and particle size pattern affects cardiovascular risk. Large, buoyant LDL particles are less atherogenic (less damaging to arteries), while small, dense LDL particles are more atherogenic. This test identifies your predominant LDL particle size pattern, providing insight beyond standard cholesterol measurements. A predominance of small, dense LDL particles is associated with higher cardiovascular risk, even with normal total LDL cholesterol. This test helps refine risk assessment and guide targeted interventions.

Small, dense LDL particles (lipoprotein beta subparticles) are a subset of low-density lipoprotein cholesterol. While total LDL level is important, the particle size matters significantly—small, dense particles penetrate artery walls more easily and are more likely to cause atherosclerosis than larger particles. High levels of small LDL particles indicate increased cardiovascular risk even with normal total cholesterol levels. This advanced lipid test provides additional insight into heart disease risk and may guide more aggressive treatment decisions for cholesterol management.

Total number of LDL particles (LDL-P) in namomoles per liter (1 nmol/L=6x10(14) particles/L)

Apolipoprotein B (ApoB) is the main protein component of LDL cholesterol particles and other atherogenic lipoproteins. Unlike standard cholesterol testing, ApoB directly counts the number of atherogenic particles in your blood, providing a more accurate cardiovascular risk assessment. One ApoB protein sits on each particle regardless of size, making ApoB a superior predictor of heart attack and stroke risk. This test is increasingly recommended for better cardiovascular risk stratification, particularly in people with metabolic syndrome or family history of early heart disease.

This test detects IgE antibodies against egg white allergens in your blood. Egg allergy is common in children but can persist into adulthood. Reactions range from oral itching and hives to gastrointestinal symptoms and anaphylaxis in severe cases. A positive test confirms egg allergy and guides dietary avoidance of eggs and egg-containing products. Note that some individuals can tolerate cooked eggs (where proteins are altered) even if they react to raw eggs, so reactions may vary by food form.